Pyramid Biosciences

Pyramid Biosciences, established in 2015, is a clinical-stage biotechnology firm focused on developing precision medicines for cancer and other molecularly-defined diseases. The company was co-founded by Jordan Leef and Dr. Kollol Pal. Dr. Pal, a serial entrepreneur with extensive experience in the pharmaceutical and biotech industries, has a history of founding and leading successful early-stage companies, including Mnemosyne Pharmaceuticals and Corbus Pharmaceuticals. Mr. Leef brought experience from the financial sector, specifically in private equity and biotechnology equity research, with previous roles at Pharos Capital Group and C.E. Unterberg, Towbin.

The company's business model centers on identifying and advancing therapies that target clinically validated biological mechanisms to address significant unmet medical needs. Pyramid Biosciences generates value through the clinical development and potential commercialization of its therapeutic pipeline, which has been supported by over $60 million in financing from investors such as Adage Capital Management, Oracle Investment Management, and J.W. Childs Associates L.P. This funding has been crucial for accelerating the company's clinical programs.

The core of Pyramid's operations is its pipeline of drug candidates targeting the tropomyosin receptor kinase (TRK) family of receptors. One of its leading programs is PBI-200, an orally-active, central nervous system (CNS) penetrant TRK inhibitor. This drug is engineered to treat a variety of genetically defined cancers, including primary and metastatic brain tumors, and is designed to overcome resistance seen in other TRK inhibitor therapies. Another significant asset is PBI-100, a topical TRK inhibitor being developed for dermatological conditions like psoriasis and atopic dermatitis due to its anti-itch, anti-inflammatory, and antiproliferative properties. In April 2023, the company expanded its oncology portfolio by licensing GQ1010, an antibody-drug conjugate (ADC) targeting TROP2, from GeneQuantum Healthcare for development and commercialization outside of Greater China. The company was acquired by Biohaven in January 2024.

Keywords: Pyramid Biosciences, clinical-stage biotechnology, precision oncology, TRK inhibitors, cancer therapies, dermatology, PBI-200, PBI-100, antibody-drug conjugate, TROP2, Kollol Pal, Jordan Leef, molecularly-defined diseases, CNS penetrant, solid tumors, atopic dermatitis, psoriasis, venture capital, biopharmaceuticals, oncology drug development